Relacorilant FDA 2026 Ovarian Cancer — PatSnap Eureka
Relacorilant in Platinum-Resistant Ovarian Cancer: ROSELLA Trial & FDA Decision
Relacorilant is a selective glucocorticoid receptor (GR) antagonist being evaluated in combination with nab-paclitaxel in the ROSELLA trial for platinum-resistant ovarian cancer — a setting with limited therapeutic options and poor prognosis. An FDA decision is anticipated in July 2026.
Glucocorticoid Receptor Antagonism as a Strategy to Overcome Platinum Resistance
Relacorilant is a selective glucocorticoid receptor (GR) antagonist under investigation in platinum-resistant ovarian cancer (PROC) — a setting with limited therapeutic options and poor prognosis. By blocking GR signaling, relacorilant targets a key mechanism through which ovarian cancer cells evade standard chemotherapy.
Key mechanistic research angles include glucocorticoid receptor-mediated chemotherapy resistance in ovarian cancer, GR-PI3K-AKT signaling crosstalk, and GR isoform expression in PROC tumors. GR expression has also been identified as a potential biomarker of platinum resistance in high-grade serous ovarian cancer, a finding with significant implications for patient selection in the ROSELLA trial.
The combination of relacorilant with nab-paclitaxel is the central therapeutic hypothesis of the ROSELLA program. Taxane-based regimens have established activity in ovarian cancer, and the addition of GR blockade via relacorilant is designed to restore chemosensitivity in tumors where glucocorticoid signaling has driven resistance. PatSnap's life sciences platform provides deep patent and literature coverage of this mechanism space.
Independent research from NIH and the broader oncology literature has established the biological rationale for GR-targeted therapy in solid tumors, supporting the scientific premise of the ROSELLA trial design.
Four Critical Research Angles for Relacorilant in PROC
Analysts seeking comprehensive intelligence on relacorilant should pursue these four complementary search dimensions, as identified through the PatSnap Eureka framework.
Composition-of-Matter & Method-of-Use Patents
Relacorilant composition-of-matter and method-of-use patents filed by Corcept Therapeutics in the US jurisdiction represent the core IP landscape. GR antagonist and taxane combination claims are a key area of patent activity for analysts to map. PatSnap Analytics surfaces these filings across jurisdictions.
Corcept Therapeutics · US JurisdictionROSELLA Phase 2/3 Trial Design & Efficacy Readouts
The ROSELLA trial evaluates relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Literature intelligence on trial design, GR expression as a biomarker of platinum resistance, and efficacy data in high-grade serous ovarian cancer is central to this research angle.
ROSELLA · Phase 2/3 · Nab-PaclitaxelFDA NDA / sNDA Submissions & PDUFA Date
FDA NDA or sNDA submissions for relacorilant, 505(b)(1) or 505(b)(2) pathway signals, and PDUFA date documentation are the key regulatory intelligence targets. The FDA decision is anticipated in July 2026. FDA.gov tracks official PDUFA timelines.
FDA · July 2026 · PDUFAGR-PI3K-AKT Crosstalk & GR Isoform Expression
Glucocorticoid receptor-mediated chemotherapy resistance in ovarian cancer, GR-PI3K-AKT signaling crosstalk, and GR isoform expression in PROC tumors are the primary mechanistic research angles. Understanding these pathways is essential for interpreting ROSELLA efficacy data and predicting patient response.
GR-PI3K-AKT · GR Isoforms · PROCRelacorilant Research Intelligence: Key Dimensions Visualised
The four research angles for relacorilant span patent, literature, regulatory, and mechanistic dimensions — each requiring distinct intelligence tools and data sources.
Relacorilant Intelligence Coverage by Research Angle
Four distinct research angles define the relacorilant intelligence landscape in platinum-resistant ovarian cancer, each contributing unique evidence for the July 2026 FDA decision.
Relacorilant GR Antagonism Mechanism in PROC
Relacorilant blocks glucocorticoid receptor signaling to restore chemosensitivity in platinum-resistant ovarian cancer tumors where GR-PI3K-AKT crosstalk drives resistance.
Relacorilant Regulatory Pathway to FDA Decision
Understanding the regulatory journey from ROSELLA trial data to the anticipated July 2026 FDA decision requires tracking three interconnected stages of evidence generation and submission.
Why Platinum-Resistant Ovarian Cancer Represents an Urgent Unmet Need
PROC is defined by limited therapeutic options and poor prognosis, making the relacorilant program a high-stakes regulatory event for patients and the oncology field.
Limited Therapeutic Options in PROC
Platinum-resistant ovarian cancer is a setting with limited therapeutic options and poor prognosis. The ROSELLA trial addresses this unmet need by combining GR antagonism with nab-paclitaxel to overcome a key resistance mechanism.
GR Expression as a Biomarker of Resistance
GR expression has been identified as a potential biomarker of platinum resistance in high-grade serous ovarian cancer. This finding has significant implications for patient selection in the ROSELLA program and potential label negotiations with the FDA.
GR-PI3K-AKT Signaling Crosstalk
Glucocorticoid receptor-mediated chemotherapy resistance in ovarian cancer involves GR-PI3K-AKT signaling crosstalk — a mechanistic insight that underpins the rationale for combining relacorilant with taxane-based chemotherapy in PROC.
Relacorilant in the PROC Treatment Landscape
Relacorilant's GR antagonist mechanism represents a novel approach in a setting where existing options — including other taxane combinations and PARP inhibitors — have shown limited activity in platinum-resistant disease.
| Approach | Mechanism | Setting | Key Challenge in PROC |
|---|---|---|---|
| Relacorilant + Nab-Paclitaxel | Selective GR antagonism + taxane | Platinum-resistant ovarian cancer | GR-PI3K-AKT resistance reversal — ROSELLA trial ongoing |
| Standard Taxane Monotherapy | Microtubule stabilisation | Platinum-resistant OC | Limited activity without GR resistance blockade |
| PARP Inhibitors | DNA damage response inhibition | Platinum-sensitive / BRCA-mutated | Reduced benefit in platinum-resistant, BRCA wild-type disease |
| Bevacizumab Combinations | Anti-VEGF angiogenesis inhibition | Recurrent OC including PROC | Modest PFS benefit; GR-mediated resistance not addressed |
Track Competitive Intelligence for Relacorilant in Real Time
PatSnap Eureka monitors patent filings, trial registrations, and regulatory submissions across the PROC treatment landscape.
Relacorilant FDA 2026 & ROSELLA — Key Questions Answered
Relacorilant is a selective glucocorticoid receptor (GR) antagonist under investigation in platinum-resistant ovarian cancer (PROC). It targets glucocorticoid receptor-mediated mechanisms that contribute to chemotherapy resistance, and is being evaluated in combination with nab-paclitaxel in the ROSELLA trial.
The ROSELLA trial evaluates relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer (PROC), a setting with limited therapeutic options and poor prognosis.
An FDA decision on relacorilant is anticipated in July 2026, based on the regulatory timeline associated with the ROSELLA trial program developed by Corcept Therapeutics.
Platinum-resistant ovarian cancer (PROC) is a setting with limited therapeutic options and poor prognosis. Resistance mechanisms, including glucocorticoid receptor-mediated signaling, reduce the effectiveness of standard chemotherapy regimens.
Relacorilant is being developed by Corcept Therapeutics, which has pursued GR antagonist oncology programs including NDA or sNDA submissions for relacorilant in ovarian cancer indications.
Key mechanistic research angles include glucocorticoid receptor-mediated chemotherapy resistance in ovarian cancer, GR-PI3K-AKT signaling crosstalk, GR isoform expression in PROC tumors, and GR expression as a biomarker of platinum resistance in high-grade serous ovarian cancer.
Still have questions? Let PatSnap Eureka search the relacorilant patent and literature landscape for you.
Ask PatSnap Eureka About RelacorilantStay Ahead of the Relacorilant FDA Decision in July 2026
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — search patents, literature, and regulatory filings for relacorilant and the PROC treatment landscape instantly.
References
- National Institutes of Health (NIH) — Glucocorticoid receptor signaling and chemotherapy resistance research
- U.S. Food and Drug Administration (FDA) — NDA/sNDA submissions and PDUFA date documentation for oncology drugs
- ClinicalTrials.gov — ROSELLA trial registration: relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer
- PatSnap Life Sciences — Patent and literature intelligence for oncology drug development
- PatSnap Analytics — IP landscape analysis for GR antagonist and taxane combination patents
- PatSnap Customer Success — Life sciences R&D intelligence case studies
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.